Drug Trial Radar · NCT06083207
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
116
Planned (sponsor's estimate)
Start
Jul 29, 2024
Primary completion
Oct 31, 2026
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 23\~116 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma.
Conditions
- Multiple Myeloma
Interventions
IBI3003Drug
Subjects will receive IBI3003 on Day 1 in a 28-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and pharmacokinetic(PK) data), until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: Up to 30 days post last dose
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Wollongong Private Hospital
Wollongong, New South Wales, Australia · Suspended
Austin Hospital
Heidelberg, Victoria, Australia · Suspended
St Vincent's Hospital
Melbourne, Victoria, Australia · Suspended
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
The first Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China · Not yet recruiting
Tongji Medical College of HUST Tongji Hospital
Wuhan, Hubei, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Not yet recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Not yet recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Not yet recruiting
ZhongShan Hospital FuDan University
Shanghai, Shanghai Municipality, China · Recruiting
The First Affiliated Hospital of XI'AN Jiaotong University
Xian, Shanxi, China · Not yet recruiting
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.